Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review

被引:26
|
作者
Couteau, Nicolas [1 ]
Duquesne, Igor [2 ]
Frederic, Panthier [1 ]
Thiounn, Nicolas [1 ]
Timsit, Marc-Olivier [1 ]
Mejean, Arnaud [1 ]
Pinar, Ugo [3 ]
Audenet, Francois [1 ]
机构
[1] Univ Paris, Serv Urol, Hop Europeen Georges Pompidou, F-75015 Paris, France
[2] Univ Paris, Serv Urol, Hop Cochin, F-75014 Paris, France
[3] Sorbonne Univ, Serv Urol, Hop La Pitie Salpetriere, F-75013 Paris, France
关键词
benign prostatic hyperplasia; ejaculation; endoscopic enucleation; anatomy; ejaculation disorders; URINARY-TRACT SYMPTOMS; HOLMIUM LASER ENUCLEATION; TRANSURETHRAL RESECTION; SEXUAL FUNCTION; RANDOMIZED-TRIAL; SINGLE-CENTER; DOUBLE-BLIND; EFFICACY; MEN; SAFETY;
D O I
10.3390/jcm10245788
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Benign prostatic hyperplasia (BPH) is commonly responsible for lower urinary tract symptoms (LUTS) in men aged 50 or over. Sexual dysfunctions, such as ejaculatory disorders (EjD), go along with LUTS but are frequently overlooked in the initial evaluation. This review aimed to detail BPH-related EjD, as well as their modifications by medical, surgical, and interventional treatments. Methods: We conducted a narrative review looking for publications between 1990 and 2020, regarding physiopathology, epidemiology, evaluation, and therapeutic management (medical, surgical, and interventional) of BPH-related EjD. Results: Sixty-five articles were included in our final analysis. Forty-six percent of men presenting with LUTS reported EjD. If the prevalence increases with age and LUTS severity, the functional impairment is not correlated with age. Several self-questionnaires evaluated the sexual function, but only four approaches are specific to EjD. Medical therapies were exposed to anejaculation, rather than retrograde ejaculation (RE) (4-30% (alpha-blockers), 4-18% (5-alpha-reductase inhibitors)). Regarding surgical therapies, trans-urethral resection of the prostate (TURP) and incision of the prostate (TUIP) are associated with 50-70% and 21-35% of RE. The RE rate is important after open simple prostatectomy but can be reduced with robotic approaches and urethral sparing techniques (19%). Anatomic endoscopic enucleation of the prostate (AEEP) with or without a laser source is associated with an 11-36% RE rate, according to supramontanal preservation. Recent surgical techniques (Rezum (c), Aquablation (c), or Urolift (c)) were developed to preserve antegrade ejaculation with promising short-term results. Regardless of the surgical approach, anatomic studies suggest that the preservation of peri-montanal tissue (7.5 mm laterally; 10 mm proximally) is primordial to avoid post-operative RE. Finally, prostate artery embolization (PAE) limits the RE rate but exposes it to a 12 months 10% re-intervention rate. Conclusion: EjD concerns almost half of the patients presenting BPH-related LUTS. Initial evaluation of EjD impairment is primordial before medical or surgical therapy. Peri-montanal tissue preservation represents a key point for antegrade ejaculation preservation, regardless of the surgical option.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Urethral Lift for Benign Prostatic Hyperplasia: A Comprehensive Review of the Literature
    Larcher, Alessandro
    Broglia, Luigi
    Lughezzani, Giovanni
    Mistretta, Francesco
    Abrate, Alberto
    Lista, Giuliana
    Fossati, Nicola
    Sangalli, Mattia
    Kuefner, Dana
    Cestari, Andrea
    Buffi, Nicolomaria
    Lazzeri, Massimo
    Guazzoni, Giorgio
    Montorsi, Francesco
    CURRENT UROLOGY REPORTS, 2013, 14 (06) : 620 - 627
  • [2] The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
    Bearelly, Priyanka
    Avellino, Gabriella Juliet
    FERTILITY AND STERILITY, 2021, 116 (03) : 611 - 617
  • [3] Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
    Corona, G.
    Tirabassi, G.
    Santi, D.
    Maseroli, E.
    Gacci, M.
    Dicuio, M.
    Sforza, A.
    Mannucci, E.
    Maggi, M.
    ANDROLOGY, 2017, 5 (04) : 671 - 678
  • [4] Modern best practice in the management of benign prostatic hyperplasia in the elderly
    Bortnick, Eric
    Brown, Conner
    Simma-Chiang, Vannita
    Kaplan, Steven A.
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
  • [5] Sexuality and Management of Benign Prostatic Hyperplasia with Alfuzosin: SAMBA Thailand
    Leungwattanakij, Somboon
    Watanachote, Damrongpun
    Noppakulsatit, Patra
    Petchpaibuol, T.
    Choeypunt, Nopporn
    Tongbai, Thanasak
    Wanamkang, Teerawan
    Lojanapiwat, Bunnakij
    Permpongkosol, Sompol
    Tantiwong, Anupan
    Pripatnanont, Chusak
    Akarasakul, Danaipan
    Kongwiwatanakul, Somsak
    Chotikawanich, Ekarat
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (09) : 3115 - 3126
  • [6] A comprehensive review of medical therapy on benign prostatic hyperplasia
    Sugianto, R.
    Tirtayasa, P. M. W.
    Duarsa, G. W. K.
    SEXOLOGIES, 2022, 31 (01) : 52 - 60
  • [7] Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review
    Abid, Ahmad
    Piperdi, Huzaifa
    Babar, Mustufa
    Loloi, Justin
    Moutwakil, Ahmed
    Azhar, Umair
    Maria, Pedro
    Small, Alexander
    PROSTATE, 2024, 84 (10) : 895 - 908
  • [8] Advances in Outpatient Therapies and Treatment of Benign Prostatic Hyperplasia A Comprehensive Review for Men's Health
    Helman, Talia A.
    Browne, Brendan M.
    MEDICAL CLINICS OF NORTH AMERICA, 2024, 108 (05) : 981 - 991
  • [9] Benign prostatic hyperplasia
    Hernandez, Sarelis Infante
    Rivas, Juan Gomez
    Sierra, Jesus Moreno
    MEDICINA CLINICA, 2024, 163 (08): : 407 - 414
  • [10] Options for the Treatment of Benign Prostatic Hyperplasia
    Plante, Mark
    Wachterman, Jared
    Perrapato, Scott
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2012, 22 (04): : 281 - 287